Merck & Co gets approval for ENFLONSIA vaccine to prevent respiratory syncytial virus in infants

Merck & Co., Inc. (NYSE:MRK) receives approval for ENFLONSIA to prevent respiratory syncytial virus in infants under 8 months. The vaccine simplifies dosing logistics and has shown a 60.5% reduction in medically attended infections and an 84.3% decrease in hospitalizations. Merck & Co. operates in the Pharmaceuticals and Animal Health Segments, known for Keytruda and Gardasil. While MRK offers investment potential, some AI stocks present greater upside with less risk. For those interested, a report on the best short-term AI stock is available. No disclosures.

Read more at Yahoo Finance: Merck & Co (MRK) Announces the Approval of ENFLONSIA